We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+15.57%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$759M
AUM Growth
+$1.33M
Cap. Flow
-$40.4M
Cap. Flow %
-5.32%
Top 10 Hldgs %
61.45%
Holding
63
New
9
Increased
18
Reduced
13
Closed
9
Avg Time Held Equity + Options
6.2 quarters
Top 10 Avg Time Held Equity + Options
5.2 quarters
Top 20 Avg Time Held Equity + Options
6.2 quarters
Avg Time Held Equity only
6.3 quarters
Top 10 Avg Time Held Equity only
5.2 quarters
Top 20 Avg Time Held Equity only
6.2 quarters

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$23.3M
2
IRON icon
Disc Medicine
IRON
+$15.3M
3
CATX icon
Perspective Therapeutics
CATX
+$14.7M
4
MGTX icon
MeiraGTx Holdings
MGTX
+$13.2M
5
QTTB icon
Q32 Bio
QTTB
+$4.95M

Top Sells

Rank Stock Value
1
HROW icon
Harrow
HROW
+$47.2M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$20.1M
3
CGON icon
CG Oncology
CGON
+$17.9M
4
ALKS icon
Alkermes
ALKS
+$13.7M
5
OCUL icon
Ocular Therapeutix
OCUL
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.06B
$99.9M 13.15%
2,832,230
-1,072,770
-27% -$47.2M
2018 Q3
30 quarters
LQDA icon
2
Liquidia Corp
LQDA
$2.41B
$88.8M 11.7%
2,545,000
+110,000
+5% +$4.08M
2021 Q4
17 quarters
ETON icon
3
Eton Pharmaceutcials
ETON
$1.55B
$70.6M 9.3%
2,860,000
– –
2018 Q4
29 quarters
SLGL icon
4
Sol-Gel Technologies
SLGL
$230M
$39.6M 5.22%
500,000
+46,261
+10% +$3.34M
2025 Q3
2 quarters
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$6.05B
$35.3M 4.65%
123,000
-207,000
-63% -$20.1M
2022 Q2
15 quarters
APGE icon
6
DELISTED
Apogee Therapeutics
APGE
$32.8M 4.32%
390,000
+1,743
+0.4% +$127K
2025 Q3
2 quarters
IRON icon
7
Disc Medicine
IRON
$2.19B
$26.9M 3.55%
421,000
+221,000
+111% +$15.3M
2025 Q1
4 quarters
URGN icon
8
UroGen Pharma
URGN
$1.85B
$25.7M 3.39%
1,430,000
+1,161,577
+433% +$23.3M
2025 Q4
1 quarter
CBIO icon
9
Crescent Biopharma
CBIO
$500M
$24.1M 3.18%
1,312,615
+134,315
+11% +$1.54M
2025 Q4
1 quarter
STOK icon
10
Stoke Therapeutics
STOK
$1.45B
$22.8M 3%
700,000
+5,000
+0.7% +$164K
2024 Q4
5 quarters
CATX icon
11
Perspective Therapeutics
CATX
$263M
$19.5M 2.57%
4,675,000
+3,490,500
+295% +$14.7M
2025 Q4
1 quarter
RZLT icon
12
Rezolute
RZLT
$452M
$19.2M 2.53%
6,300,000
+12,844
+0.2% +$38.5K
2024 Q3
6 quarters
MGTX icon
13
MeiraGTx Holdings
MGTX
$968M
$18.4M 2.42%
2,123,259
+1,732,415
+443% +$13.2M
2025 Q4
1 quarter
TGTX icon
14
TG Therapeutics
TGTX
$8.31B
$17.8M 2.34%
535,000
– –
2023 Q3
10 quarters
SNWV icon
15
SANUWAVE Health Inc
SNWV
$47.3M
$17M 2.23%
981,267
– –
2025 Q1
4 quarters
EWTX icon
16
Edgewise Therapeutics
EWTX
$3.99B
$15.8M 2.07%
500,000
– –
2022 Q1
16 quarters
ACOG icon
17
Alpha Cognition
ACOG
$191M
$14.1M 1.85%
2,561,950
+491,166
+24% +$2.79M
2025 Q3
2 quarters
ANNX icon
18
Annexon
ANNX
$726M
$12.9M 1.7%
2,331,761
-268,239
-10% -$1.51M
2025 Q3
2 quarters
ALMS icon
19
Alumis Inc
ALMS
$852M
$12.1M 1.6%
550,000
+15,000
+3% +$375K
2025 Q2
3 quarters
CDXS icon
20
Codexis
CDXS
$148M
$11.1M 1.46%
6,785,000
-4,738
-0.1% -$6.75K
2014 Q1
48 quarters
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.03B
$10.5M 1.39%
100,000
-5,000
-5% -$443K
2023 Q4
9 quarters
RVMD icon
22
Revolution Medicines
RVMD
$40.4B
$9.72M 1.28%
100,000
– –
2025 Q2
3 quarters
XOMA icon
23
DELISTED
Xoma
XOMA
$9.41M 1.24%
300,000
+7,410
+3% +$198K
2017 Q1
36 quarters
QTTB icon
24
Q32 Bio
QTTB
$237M
$8.06M 1.06%
1,256,228
+1,042,865
+489% +$4.95M
2025 Q4
1 quarter
MBX icon
25
MBX Biosciences
MBX
$2.39B
$7.76M 1.02%
260,000
– –
2025 Q1
4 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2026 Portfolio in Review

As of Q1 2026, Opaleye Management held 63 positions worth $759M, up 0.18% from $758M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management withdrew a net $40.4M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Alkermes, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Editas Medicine worth $4.76M.

  • Opaleye Management's largest Q1 2026 buy was Editas Medicine: 1,926,997 shares worth $4.76M.
  • Opaleye Management added most to UroGen Pharma in Q1 2026, an estimated $23.3M increase.
  • Opaleye Management's biggest Q1 2026 reduction was Harrow, cutting an estimated $47.2M.
  • Opaleye Management fully exited Alkermes in Q1 2026, selling an estimated $13.7M.
  • Opaleye Management's ten largest holdings make up 61% of its $759M portfolio in Q1 2026.
  • Opaleye Management opened 9 new positions and closed 9 in Q1 2026.
  • Opaleye Management's portfolio value rose 0.18% quarter-over-quarter to $759M.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.